MA50163A - Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité - Google Patents

Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité

Info

Publication number
MA50163A
MA50163A MA050163A MA50163A MA50163A MA 50163 A MA50163 A MA 50163A MA 050163 A MA050163 A MA 050163A MA 50163 A MA50163 A MA 50163A MA 50163 A MA50163 A MA 50163A
Authority
MA
Morocco
Prior art keywords
infertility
fertility
compositions
sub
treatment
Prior art date
Application number
MA050163A
Other languages
English (en)
Inventor
Vittorio Unfer
Original Assignee
Lo Li Pharma Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lo Li Pharma Srl filed Critical Lo Li Pharma Srl
Publication of MA50163A publication Critical patent/MA50163A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
MA050163A 2017-09-19 2018-09-18 Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité MA50163A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000104446A IT201700104446A1 (it) 2017-09-19 2017-09-19 Compositions, uses and methods for treatment of infertility and subfertility

Publications (1)

Publication Number Publication Date
MA50163A true MA50163A (fr) 2020-07-29

Family

ID=60991464

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050163A MA50163A (fr) 2017-09-19 2018-09-18 Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité

Country Status (19)

Country Link
US (2) US11364282B2 (fr)
EP (1) EP3684372A1 (fr)
KR (1) KR102468673B1 (fr)
AR (1) AR112700A1 (fr)
CA (1) CA3075582A1 (fr)
CL (1) CL2020000684A1 (fr)
CO (1) CO2020002658A2 (fr)
EA (1) EA202090790A1 (fr)
IT (1) IT201700104446A1 (fr)
JO (1) JOP20200065A1 (fr)
MA (1) MA50163A (fr)
MX (1) MX2020002914A (fr)
PE (1) PE20200890A1 (fr)
PH (1) PH12020550077A1 (fr)
PY (1) PY1880729A (fr)
SG (1) SG11202001756YA (fr)
UY (1) UY37885A (fr)
WO (1) WO2019057709A1 (fr)
ZA (1) ZA202002366B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053685A1 (fr) * 2019-09-20 2021-03-25 Ramesh Patodia Nouvelle formulation nutraceutique pour le syndrome des ovaires polykystiques (sopk)
IT202300004827A1 (it) * 2023-03-14 2024-09-14 Lo Li Pharma Srl Composizione per uso nel trattamento della sindrome dell’ovaio policistico
IT202300002769A1 (it) * 2023-02-17 2024-08-17 Lo Li Pharma Srl Composizione per uso nel trattamento della sindrome dell’ovaio policistico
KR20250145022A (ko) * 2023-02-17 2025-10-13 로.리. 파르마 에스.알.엘 다낭성 난소 증후군의 치료에서의 사용을 위한 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6876498A (en) 1997-04-03 1998-10-22 Point Biomedical Corporation Intravesical drug delivery system
EP1228707A1 (fr) 2001-02-01 2002-08-07 Campina Melkunie B.V. Utilisation d'alpha-lactalbumine comme agent prébiotique
GB0205347D0 (en) * 2002-03-07 2002-04-24 Svanborg Catharina Biologically active complex
ITRM20070341A1 (it) * 2007-06-20 2008-12-21 Lo Li Pharma Srl Formulazione integrativa inofolic finalizzata al controllo dell'induzione dell'ovulazione in programmi di procreazione medicalmente assistita
ITFI20110252A1 (it) * 2011-11-22 2013-05-23 Lo Li Pharma Srl Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo.
MX2012010488A (es) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Formula infantil para el optimo crecimiento, proteccion gastrointestinal y proteccion inmunologica de infantes.
US20140294795A1 (en) * 2013-03-28 2014-10-02 Houn Simon Hsia Nutritional Composition
MX374421B (es) * 2014-08-08 2025-03-06 Soc Des Produits Nestle S A Star Mioinositol y uno o más probióticos y sus usos.
CN104365997A (zh) * 2014-12-14 2015-02-25 河南联合英伟饲料有限公司 一种家畜幼仔奶粉饲料

Also Published As

Publication number Publication date
US20200215165A1 (en) 2020-07-09
PE20200890A1 (es) 2020-09-07
KR102468673B1 (ko) 2022-11-17
SG11202001756YA (en) 2020-04-29
PH12020550077A1 (en) 2022-07-18
CO2020002658A2 (es) 2020-05-15
CL2020000684A1 (es) 2020-08-21
AR112700A1 (es) 2019-11-27
WO2019057709A1 (fr) 2019-03-28
US11364282B2 (en) 2022-06-21
EP3684372A1 (fr) 2020-07-29
KR20200092939A (ko) 2020-08-04
PY1880729A (es) 2021-04-06
EA202090790A1 (ru) 2020-06-17
CA3075582A1 (fr) 2019-03-28
MX2020002914A (es) 2020-08-17
ZA202002366B (en) 2024-09-25
BR112020005537A2 (pt) 2020-10-06
JOP20200065A1 (ar) 2020-03-17
IT201700104446A1 (it) 2019-03-19
UY37885A (es) 2018-11-30
US20220062388A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MA47719A (fr) Esketamine pour le traitement de la dépression
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3298140A4 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3411504A4 (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
EP3541408A4 (fr) Compositions et méthodes pour le traitement de l'angiogenèse aberrante
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l'hyperhidrose
EP3684400A4 (fr) Méthodes pour traiter la nétose et l'activation des neutrophiles
EP3458079A4 (fr) Compositions et méthodes pour le traitement de l'acné
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3634431A4 (fr) Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP4218736A3 (fr) Compositions à base de 15-hepe
EP3399993A4 (fr) Méthodes et compositions pour la prévention et le traitement d'une dystrophie musculaire de duchenne
EP3331526A4 (fr) Enzymes de dégradation de la nicotine pour le traitement d'une dépendance à la nicotine et d'un empoisonnement à la nicotine
EP3801478A4 (fr) Méthodes et compositions pour la prévention ou le traitement de la calciphylaxie
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3638270A4 (fr) Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité